Kathleen M. Whalen - 02 Nov 2021 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Role
SVP & Chief Ethics Officer
Signature
/s/ Kevin A. Ball, Attorney-in-Fact
Issuer symbol
HCA
Transactions as of
02 Nov 2021
Net transactions value
-$1,571,762
Form type
4
Filing time
04 Nov 2021, 18:22:28 UTC
Previous filing
26 Jul 2021
Next filing
01 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Options Exercise $159,500 +3,325 +37% $47.97* 12,202 02 Nov 2021 Direct
transaction HCA Common Stock Options Exercise $344,800 +5,000 +41% $68.96 17,202 02 Nov 2021 Direct
transaction HCA Common Stock Tax liability $1,120,464 -4,510 -26% $248.44 12,692 02 Nov 2021 Direct
transaction HCA Common Stock Sale $955,598 -3,815 -30% $250.48 8,877 04 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCA Stock Appreciation Right Options Exercise $0 -2,625 -100% $0.000000* 0 02 Nov 2021 Common Stock 2,625 $47.97 Direct F2
transaction HCA Stock Appreciation Right Options Exercise $0 -700 -100% $0.000000* 0 02 Nov 2021 Common Stock 700 $47.97 Direct F3
transaction HCA Stock Appreciation Right Options Exercise $0 -5,000 -100% $0.000000* 0 02 Nov 2021 Common Stock 5,000 $68.96 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.141 to $250.84, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The stock appreciation rights vested in four equal annual installments beginning on February 5, 2015.
F3 The stock appreciation rights vested at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the achievement of certain annual EBITDA performance targets.
F4 The stock appreciation rights vested in four equal annual installments beginning on February 4, 2016.